Illumina, Inc. (ILMN): Price and Financial Metrics

Illumina, Inc. (ILMN): $413.53

5.11 (+1.25%)

POWR Rating

Component Grades













Add ILMN to Watchlist
Sign Up

Industry: Biotech


of 491

in industry

ILMN Stock Summary

  • With a market capitalization of $58,845,847,000, Illumina Inc has a greater market value than 95.8% of US stocks.
  • Price to trailing twelve month operating cash flow for ILMN is currently 54.49, higher than 91.14% of US stocks with positive operating cash flow.
  • ILMN's price/sales ratio is 18.17; that's higher than the P/S ratio of 88.85% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are NTES, VMW, DXCM, ATVI, and SPOT.
  • ILMN's SEC filings can be seen here. And to visit Illumina Inc's official web site, go to

ILMN Stock Price Chart Interactive Chart >

Price chart for ILMN

ILMN Price/Volume Stats

Current price $413.53 52-week high $555.77
Prev. close $408.42 52-week low $260.42
Day low $410.04 Volume 396,024
Day high $415.81 Avg. volume 1,163,219
50-day MA $420.14 Dividend yield N/A
200-day MA $368.85 Market Cap 60.37B

Illumina, Inc. (ILMN) Company Bio

Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.

ILMN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$413.53$92.27 -77%

Below please find a table outlining a discounted cash flow forecast for ILMN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Illumina Inc ranked in the 23th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 77%. The most interesting components of our discounted cash flow analysis for Illumina Inc ended up being:

  • The company's balance sheet shows it gets 97% of its capital from equity, and 3% of its capital from debt. Notably, its equity weight is greater than 80.6% of US equities in the Healthcare sector yielding a positive free cash flow.
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 13.03% of the free cash flow producing stocks we're observing.
  • ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 47.18% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ILMN, try FZMD, XRAY, LGND, MTD, and NUVA.

ILMN Latest News Stream

Event/Time News Detail
Loading, please wait...

ILMN Latest Social Stream

Loading social stream, please wait...

View Full ILMN Social Stream

Latest ILMN News From Around the Web

Below are the latest news stories about Illumina Inc that investors may wish to consider to help them evaluate ILMN as an investment opportunity.

Dr. Gottlieb: Summer Covid risk dropping but winter could see case spike

Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, joined "Squawk Box" on Thursday to discuss what he expects when it comes to the spread of coronavirus as more businesses and employers are planning to reopen over the summer and into the fall.

CNBC | April 22, 2021

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.

Yahoo | April 21, 2021

Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors

SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board. New directors comprise Troy Cox, former CEO of Foundation Medicine, Susannah Gray, former EVP and CFO of Royalty Pharma Management, and Karen McGinnis, former VP and CAO of Illumina. “We are honored to have this caliber of experience and leadership join our new board at Biosplice,” said Osman Kibar, PhD, Founder and Executive Chairman of Biosplice. “Ms. Gray, Ms. McGinnis, and Mr. Cox bring invaluable insight to our company as we continue the buildout of our alternative splicing platform and navigate the f...

Yahoo | April 20, 2021

EU to examine Illumina's $7.1 bln acquisition of Grail on antitrust grounds

EU antitrust regulators will examine Illumina Inc's proposed $7.1 billion acquisition of cancer test maker Grail Inc, the European Commission said on Tuesday, following a request from six countries on competition concerns. U.S. life sciences company Illumina announced last September that it would acquire Grail - which it previously owned before spinning it off as a separate business four years ago - by buying out investors including Inc founder Jeff Bezos. Illumina had remained the company's largest shareholder.

Yahoo | April 20, 2021

Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Illumina disagrees with the European Commission’s Directorate-General for Competition’s decision to review Illumina’s acquisition of GRAIL.

Yahoo | April 20, 2021

Read More 'ILMN' Stories Here

ILMN Price Returns

1-mo 1.65%
3-mo 1.79%
6-mo 27.81%
1-year 32.24%
3-year 73.39%
5-year 187.99%
YTD 11.76%
2020 11.53%
2019 10.61%
2018 37.27%
2017 70.64%
2016 -33.30%
Page generated in 1.0752 seconds.